Clinical Oncology Next-Generation Sequencing Market: Advancements, Precision Medicine, and Personalized Cancer Care 2029.

Spread the love

Clinical Oncology Next-Generation Sequencing Market: size was valued at US $ 7.86 Bn.in 2022 and the total revenue is expected to grow at 20.7% through 2022 to 2029, reaching nearly US$ 2.93 Bn.

Clinical Oncology Next-Generation Sequencing Market Overview:

MMR published a report on the Clinical Oncology Next-Generation Sequencing Market. The report is a combination of primary and secondary data, and it has been analyzed by domain experts from both a local and global perspective. The report provides a detailed analysis of the market size and share in each region and segment, making it an invaluable resource for investors.

Clinical Oncology Next-Generation Sequencing Market Dynamics: 

The market for next-generation sequencing in clinical oncology is anticipated to lead in the next years due to factors such as the rising incidence of cancer and technological advancements in the sector. Additionally, it is anticipated that during the anticipated era, a rise in the preference for NGS over single-gene research would present significant prospects for market expansion.

The United States saw 1.7 million new instances of cancer and 0.6 million cancer-related deaths in 2019, according to the American Cancer Society. The four most common cancers worldwide are female breast cancer, bladder cancer, prostate cancer, and lung cancer, together making up 43% of all new cancer cases. Thus, it is anticipated that the rise in cancer incidence rates worldwide would raise demand for next-generation sequencing in clinical oncology.

Click the below link for more details: https://www.maximizemarketresearch.com/request-sample/100383 

Clinical Oncology Next-Generation Sequencing Market Report Scope and Research Methodology: 

At the national, regional, and international levels, the research offers a thorough examination of the Clinical Oncology Next-Generation Sequencing market. It offers a thorough examination of the competitive environment in the property management sector, taking into account the main companies’ business plans. A summary of the major rivals of Property Management is provided in the study, together with data on their earnings, output, market share, and worldwide reach. The top players in the property management business were analysed using the SWOT method to determine their strengths and weaknesses. The report also includes detailed information on the potential, challenges, drivers, and constraints of the Clinical Oncology Next-Generation Sequencing market.

The scale of the global and regional Clinical Oncology Next-Generation Sequencing markets was estimated using a bottom-up methodology. Data on market size, market share, geographical insights, market dynamics, the performance of major players, and industry historical data were gathered using both primary and secondary research methodologies. The study also contains a thorough value chain analysis with data on distributors, customers, and raw materials that aids in understanding the Property Management manufacturing process. In addition, market attractiveness and Porter’s and PESTLE analyses are included, which aid in understanding the Clinical Oncology Next-Generation Sequencing Market both macro and micro.

Clinical Oncology Next-Generation Sequencing Market Segmentation: 

by Technology
• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing Centrifuges

With a sales share of more than 72% in 2020, the targeted sequencing and resequencing segment saw tremendous growth based on technology. The cost, time, and amount of data analysed during the sequencing of tumour samples are often reduced by targeted cancer sequencing panels. Furthermore, the therapeutic efficacy of targeted panels is enhanced by their capacity to detect malignant tumours. A 2020 JCO Precision Oncology research found that 64 percent of cancer cases can be treated clinically with NGS panels.

by Workflow
• Pre Sequencing
• Sequencing
• Data Analysis

Sequencing accounted for over 54% of overall revenue, making it the most profitable process category according to process. One of the most important stages of the workflow, sequencing calls for the usage of specialised platforms. The growth of the segment is further supported by an increase in the quantity of cancer sequencing programmes. The primary drivers of the pre-sequencing portion are the attempts of major stakeholders to lower the cost of NGS library planning. It is anticipated that NGS data analysis would become more common. The creation of advanced analytical tools by prominent industry players is driving the growth of this area. More than 2,600 tumour samples from 38 distinct cancer types were sequenced by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium.

by Application
• Screening
• Companion Diagnostics
• Other Diagnostics

According to the application, the screening generated the largest revenue share—more than 79%. It is currently believed that NGS-based research is the most efficient way to find genetic alterations in cancer patients that can be used to their advantage as a therapy. Physicians can now analyse many gene variants simultaneously thanks to this technology. Alliances and partnerships among important stakeholders, together with continuous product innovation, are expected to drive the adoption of NGS for companion diagnostics.

by End-User
• Hospitals
• Clinics
• Laboratories

Over the course of the projected period, the laboratories category emerged as the industry leader, accounting for over 65 percent of total sales, according to End User data. It takes a lot of time to set up dynamic workflows in laboratories. Because of this, most specialised labs have already created workflows based on standard operating procedures. Furthermore, thorough guidelines for processes requiring NGS testing have been built as a result of the quick development and distribution of NGS assays for clinical application. Because of this, the majority of FDA-approved evaluations demonstrate the validity of their conclusions through the use of tried-and-true controls, criteria, and performance attributes.

To know about the Research Methodology :- Request Free Sample Report

Clinical Oncology Next-Generation Sequencing Market Key Players: 

• Illumina, Inc.
• QIAGEN
• Thermo Fisher Scientific, Inc.
• F. Hoffman-La Roche Technologies
• Agilent Technologies
• Myriad Genetics
• Foundation Medicine
• Pacific Bioscience
• Oxford Nanopore Technologies Ltd.
• Beijing Genomics Institute (BGI)
• Perkin Elmer, Inc.
• Paradigm Diagnostics
• Caris Life Sciences
• Partek, Inc.
• Eurofins Scientific S.E.
• Bio Rad Laboratories, Inc.
• Other Key Players

Clinical Oncology Next-Generation Sequencing Market Regional Insights: 

Geographically speaking, the report is divided into a number of important nations, each of which has its own market size, growth rate, import and export figures, and information about the Clinical Oncology Next-Generation Sequencing market. These nations include the United States, Canada, Mexico, Europe, the United Kingdom, China, India, Japan, Australia, South Korea, ASEAN Countries, the rest of Asia Pacific, South America, Brazil, and the Middle East and Africa.

Key Questions answered in the Clinical Oncology Next-Generation Sequencing Market Report are:

  • What is the expected Clinical Oncology Next-Generation Sequencing Market size by 2029?
  • What will be the CAGR of the Clinical Oncology Next-Generation Sequencing Market during the forecast period?
  • Which segment held the largest share in the Clinical Oncology Next-Generation Sequencing Market?
  • How is the competitive scenario of the Clinical Oncology Next-Generation Sequencing Market?
  • Which are the key factors driving the Clinical Oncology Next-Generation Sequencing Market growth?
  • What are the factors restraining the Clinical Oncology Next-Generation Sequencing Market growth?
  • Which region holds the maximum share in the Clinical Oncology Next-Generation Sequencing Market?
  • Who are the key players in the Clinical Oncology Next-Generation Sequencing Market?

For further information, click the following link: https://www.maximizemarketresearch.com/request-sample/100383 

Key Offerings:

  • A detailed Market Overview
  • Market Share
  • Market Size
  • Market Forecast by Revenue
  • Market Dynamics- Growth drivers, Restraints, Investment Opportunities, and key trends
  • Market Segmentation- A detailed analysis of each segment and their segments
  • Competitive Landscape – Leading key players and other prominent key players.

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

[email protected]

+91 96071 95908, +91 9607365656


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →